The presence of overlapping infection of HCV and HBV affects the prognosis of liver disease HCV infection in patients with chronic liver disease, especially dual infection of HBV and HCV, may accelerate the progression of liver disease. Viral hepatitis (viralhepatitis) is a group of infectious diseases caused by a variety of different hepatitis viruses, mainly liver damage, according to the pathogenic diagnosis, there are at least five types of hepatitis viruses, namely hepatitis A, B, C, D and E viruses, which cause viral hepatitis A, B, C, D and E, respectively, namely hepatitis A (hepatitis A), hepatitis B ( hepatitis B), hepatitis C), hepatitis D) and hepatitis E). Another type of viral hepatitis, called hepatitis G, is less common. What are the prevention methods? Management of infectious sources 1, reporting and registration of suspected, confirmed, hospitalized, discharged, and deceased cases of hepatitis should be reported according to the etiology of infectious diseases, special registry and statistics. 2, isolation and disinfection of acute hepatitis A and E from the date of onset of isolation for 3 weeks; hepatitis B and C isolation until the condition is stable can be discharged. Each type of hepatitis should be hospitalized in separate rooms. Patients’ secretions, excretions, blood and contaminated medical devices and objects should be disinfected. 3, the management of child contacts of acute hepatitis A or E patients should be under medical observation for 45 days. 4. Management of blood donors Blood donors should undergo a physical examination before each blood donation, testing ALT and HBsAg (by RPHA method or ELISA method), and those with abnormal liver function and positive HBsAg should not donate blood. Anti-HCV measurement should be carried out when available, and those with positive anti-HVC should not donate blood. 5, HBsAg carriers and management of HBsAg carriers can not donate blood, can work and study as usual, but to strengthen with the prevention, should pay attention to personal hygiene and menstrual hygiene, as well as industrial hygiene, to prevent their saliva, blood and other secretions contamination of the surrounding environment, infecting others; personal eating utensils, scrapers and facial appliances, toiletries, etc. should be separated from healthy people. hBeAg positive people can not engage in the food industry. HBsAg-positive infants and children should be properly segregated from HBsAg-negative people in childcare institutions, and HBeAg-positive infants and children should not be admitted to childcare. Cut off the transmission route 1. Strengthen dietary hygiene management, water source protection, environmental hygiene management and harmless treatment of feces, and improve personal hygiene. 2.Strengthen the disinfection of all kinds of medical equipment, implement one tube for one person for injection or use disposable syringes, and disinfect medical equipment for one person for one use. Strengthen the management of blood and blood products, and do a good job of HBsAg testing of products, and those who are positive are not allowed to sell and use. Do not transfuse blood or blood products when not necessary. Use toiletries and eating utensils exclusively. Wash hands with soap and running water after contact with patients. Protection of infants to cut off mother-to-child transmission is the focus of prevention, for HBsAg-positive mothers, especially HBeAg-positive maternal infants, must be injected with hepatitis B specific immune globulin and (or) hepatitis B vaccine immediately after birth. Protection of susceptible groups 1, hepatitis A and commercially available human blood gammaglobulin and human placental blood gammaglobulin have a certain degree of protection for hepatitis A contacts; mainly for susceptible children exposed to hepatitis A patients. The dose is 0.02 to 0.05 ml per pound of body weight, and the earlier the injection, the better, no later than 7 to 14 days after exposure. Research on live hepatitis A vaccine has made significant progress and will soon be used for hepatitis A prevention. 2, hepatitis B (1) hepatitis B specific immunoglobulin: mainly used for the blockage of mother-to-child transmission, should be used in combination with hepatitis B vaccine. It can also be used for passive immunization in case of accidents. (2) Hepatitis B blood-borne vaccine or genetically engineered hepatitis B vaccine: mainly used for blocking mother-to-child transmission and neonatal prophylaxis, and should be used in combination with hepatitis B specific immune globulin to improve the protection rate. It can also be used for prevention in susceptible individuals in high-risk groups. Genetically engineered vaccines combining ex-S2, ex-S1 and S genes have also been successfully developed.